Assessing Ocular Surface Changes After Changing Glaucoma Medications

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00554411
First received: November 2, 2007
Last updated: January 29, 2013
Last verified: January 2013

November 2, 2007
January 29, 2013
November 2007
August 2011   (final data collection date for primary outcome measure)
Change in Signs and Symptoms of Ocular Surface Disease [ Time Frame: 6 months ] [ Designated as safety issue: No ]
measurable change in the tear film brek up time [ Time Frame: 6 weeks ]
Complete list of historical versions of study NCT00554411 on ClinicalTrials.gov Archive Site
Not Provided
measurable change in the corneal staining and the Ocular Surface Disease Index [ Time Frame: 6 weeks ]
Not Provided
Not Provided
 
Assessing Ocular Surface Changes After Changing Glaucoma Medications
Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be record at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients will be selected from the ophthalmology clinic of the principal investigator

  • Glaucoma
  • Monotherapy With Xalatan From 1 to 18 Months
  • Ocular Surface Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • on Xalatan monotherapy from 1 t 18 months
  • 18 years of age or older
  • has been diagnosed with ocular surface disease

Exclusion Criteria:

  • special populations such as children, pregnant females, prisoners, etc.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00554411
07-0757
No
University of Colorado, Denver
University of Colorado, Denver
Not Provided
Principal Investigator: Malik Y Kahook, M.D. Rocky mountain Lions Eye Institute
University of Colorado, Denver
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP